Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03888391 · ClinicalTrials.gov registry record · NA

12 Month Open Extension of TNS for ADHD.

A NA study of Attention Deficit Hyperactivity Disorder (ADHD), sponsored by James McGough.

Completed
Registry status
NA
Development phase
18
Enrollment target
1
Study location

NCT03888391 is a NA study of Attention Deficit Hyperactivity Disorder (ADHD) that has completed, run by James McGough. The registered enrollment target is 18 participants, below the 146-participant average among 15 other Attention Deficit Hyperactivity Disorder (ADHD) trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03888391, a NA study of Attention Deficit Hyperactivity Disorder (ADHD), has completed, sponsored by James McGough.

COMPLETED
Registry status
NA
Development phase
18 participants
Enrollment target
1
Study location

Study Summary

Participants who exhibit sufficient ADHD symptom improvement in a prior study of active TNS will be invited to continue in a 12-month extension study, designed to collect additional data on long-term response and tolerability and to provide participants ongoing clinical benefit from treatment.

Interventions

  • DEVICE Active TNS

Study Locations (1)

California

  • UCLA Semel Institute - Los Angeles

Trial Details

FieldValue
Enrollment Target 18 participants
Start Date 2014-12-01
Est. Completion 2018-05-30
Phase NA

Sponsor

James McGough

1 total trials

What the Registry Record Tells You About NCT03888391

The ClinicalTrials.gov registry entry for NCT03888391 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 146-participant average among 15 other Attention Deficit Hyperactivity Disorder (ADHD) trials with a reported enrollment target (88% lower). The listed sponsor is James McGough, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Attention Deficit Hyperactivity Disorder (ADHD) appearing as the primary indexed condition, and to 1 intervention - of which Active TNS is the first listed.

NCT03888391 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT03888391 about?

NCT03888391 is a clinical study titled "12 Month Open Extension of TNS for ADHD.". Participants who exhibit sufficient ADHD symptom improvement in a prior study of active TNS will be invited to continue in a 12-month extension study, designed to collect additional data on long-term response and tolerability and to provide participants ongoing clinical benefit from treatment.

What is the current status of trial NCT03888391?

This trial is currently completed. It is a NA study. The enrollment target is 18 participants. The study started on 2014-12-01. Estimated completion is 2018-05-30.

What conditions does trial NCT03888391 study?

This clinical trial studies the following conditions: Attention Deficit Hyperactivity Disorder (ADHD).

What interventions are being tested in trial NCT03888391?

The interventions under investigation include: Active TNS (DEVICE).

Who is sponsoring clinical trial NCT03888391?

This trial is sponsored by James McGough, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03888391 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Attention Deficit Hyperactivity Disorder (ADHD)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.